With a recent resurgence in nasal drug repurposing, this article looks at the importance of training and onboarding for intranasal rescue therapies.
The resurgence in nasal drug repurposing has been driven by several factors. From an economic perspective, partners benefit from reduced development costs, IP creation, increased market share and extended life cycle. The regulatory pathways are faster and less complex. It may also provide an opportunity to respond to a currently unmet medical need. Patients benefit too – they feel empowered because medical staff intervention and supervision can be reduced, putting patients back in greater control of their lives. And of course, nasal drug delivery does provide simplified access, often with an intuitive, user-friendly method of delivery.